Jonathan Rosenberg
Jonathan Rosenberg
Verified email at
Cited by
Cited by
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm …
JE Rosenberg, J Hoffman-Censits, T Powles, MS Van Der Heijden, ...
The Lancet 387 (10031), 1909-1920, 2016
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
S Mariathasan, SJ Turley, D Nickles, A Castiglioni, K Yuen, Y Wang, ...
Nature 554 (7693), 544-548, 2018
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
RM Samstein, CH Lee, AN Shoushtari, MD Hellmann, R Shen, ...
Nature genetics 51 (2), 202-206, 2019
Early childhood development coming of age: science through the life course
MM Black, SP Walker, LCH Fernald, CT Andersen, AM DiGirolamo, C Lu, ...
The Lancet 389 (10064), 77-90, 2017
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
AV Balar, MD Galsky, JE Rosenberg, T Powles, DP Petrylak, J Bellmunt, ...
The Lancet 389 (10064), 67-76, 2017
Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206
BI Rini, S Halabi, JE Rosenberg, WM Stadler, DA Vaena, SS Ou, L Archer, ...
Journal of Clinical Oncology 26 (33), 5422, 2008
Pneumonitis in patients treated with anti–programmed death-1/programmed death ligand 1 therapy
J Naidoo, X Wang, KM Woo, T Iyriboz, D Halpenny, J Cunningham, ...
Journal of Clinical Oncology 35 (7), 709, 2017
Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206
BI Rini, S Halabi, JE Rosenberg, WM Stadler, DA Vaena, L Archer, ...
Journal of clinical oncology 28 (13), 2137, 2010
Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/ASTRO/SUO guideline
SS Chang, BH Bochner, R Chou, R Dreicer, AM Kamat, SP Lerner, ...
The Journal of urology 198 (3), 552-559, 2017
Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial
P Sharma, MK Callahan, P Bono, J Kim, P Spiliopoulou, E Calvo, ...
The lancet oncology 17 (11), 1590-1598, 2016
Treatment of patients with metastatic urothelial cancer “unfit” for cisplatin-based chemotherapy
MD Galsky, NM Hahn, J Rosenberg, G Sonpavde, T Hutson, WK Oh, ...
Journal of clinical oncology 29 (17), 2432-2438, 2011
Enfortumab vedotin in previously treated advanced urothelial carcinoma
T Powles, JE Rosenberg, GP Sonpavde, Y Loriot, I Durán, JL Lee, ...
New England Journal of Medicine 384 (12), 1125-1135, 2021
Somatic ERCC2 Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma
EM Van Allen, KW Mouw, P Kim, G Iyer, N Wagle, H Al-Ahmadie, C Zhu, ...
Cancer discovery 4 (10), 1140-1153, 2014
Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior …
CJ Ryan, MR Smith, L Fong, JE Rosenberg, P Kantoff, F Raynaud, ...
Journal of clinical oncology 28 (9), 1481, 2010
Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma
BI Rini, MD Michaelson, JE Rosenberg, RM Bukowski, JA Sosman, ...
Journal of Clinical Oncology 26 (22), 3743-3748, 2008
Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy
JE Rosenberg, PH O’Donnell, AV Balar, BA McGregor, EI Heath, YY Evan, ...
Journal of Clinical Oncology 37 (29), 2592, 2019
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma
TK Choueiri, U Vaishampayan, JE Rosenberg, TF Logan, AL Harzstark, ...
Journal of Clinical Oncology 31 (2), 181, 2013
Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1/PD-L1 blockade in advanced urothelial cancers
MY Teo, K Seier, I Ostrovnaya, AM Regazzi, BE Kania, MM Moran, ...
Journal of Clinical Oncology 36 (17), 1685, 2018
Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials
TK Choueiri, FA Schutz, Y Je, JE Rosenberg, J Bellmunt
Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews …, 2010
Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens
J Bellmunt, TK Choueiri, R Fougeray, FAB Schutz, Y Salhi, E Winquist, ...
Journal of Clinical Oncology 28 (11), 1850-1855, 2010
The system can't perform the operation now. Try again later.
Articles 1–20